COVID-19

By Rob DiCicco, June 11, 2020
The novel coronavirus (COVID-19) pandemic is an unprecedented crisis that has galvanized the global scientific community around the search for a viable vaccine and effective therapies. This incredible commitment to science may ultimately pay dividends, but each passing day is critical as we seek to stem the tide of this deadly pandemic. There is a collective sense of urgency to consider incremental ways to expediate the process to get treatments to patients and our IBM® Clinical Development (ICD) solution is designed to help address a challenge such as this.

THUNDER BAY, ONTARIO (June 08, 2020) – IGY Life Sciences today announced it will be collaborating with clinical data and regulatory experts, MMS Holdings (MMS), to further the development of IgY-110, an anti-CoV2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed.

Canton, Mich. (March 20, 2020) — MMS Holdings announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.

by Prasad M. Koppolu, March 12, 2020
I would like to take a moment and share our commitment to the highest levels of health and improving lives worldwide, amidst the outbreak of COVID-19.